Blood and Marrow Volumes and Survival Outcomes

Find a research trial at Baylor.

Feinstein LC, Sandmaier BM, Maloney DG, Maris MB, Gooley TA, Chauncey TR, Hegenbart U, McSweeney, PA, Stuart MJ, Forman SJ, Agura ED, Pulsipher MA, Blume KG, Niederwieser DW, Storb RF: Allografting after non-myeloablative conditioning as a treatment following a failed conventional hematopoietic cell transplant. BBMT (submitted Oct 2002).

Georges GE, Maris M, Sandmaier BM, Malone DG, Feinstein L, Niederweiser D, Shizuru JA, McSweeney PA, Chauncey TR, Agura E, Little MT, Sahebi F, Hegenbart U, Pulsipher MA, Bruno B, Forman S, Woolfrey AE, Radich JP, Blume KG, Storb R.Related and unrelated non-myeloablative hematopoietic stem cell transplantation for malignant diseases. Int J Hematol 2002;76 Suppl 1:184-189.

Sandmaier BM, Maloney DG, Gooley, TA, Shizuru J, Hegenbart U, Sahebi F, Chauncey T, Bruno B, Agura E, McSweeney P, Forman S, Niederwieser D, Blume K, Storb R: Low-dose TBI Conditioning for Hematopoietic Stem Cell Transplants (HSCT) from HLA-matched Related Donors for Patients with Hematologic Malignancies: Influence of Fludarabine or Cytoreductive Autografts on Outcome. (Abstract submitted 2002)